Investment company Hennessy Japan Fund buys Japan Tobacco Inc, Recruit Holdings Co, Sumitomo Mitsui Financial Group Inc, ASICS Corp, Terumo Corp, Kubota Corp, Shimano Inc during the 3-months ended 2017-04-30, according to the most recent filings of the investment company, Hennessy Japan Fund. As of 2017-04-30, Hennessy Japan Fund owns 22 stocks with a total value of $172 million. These are the details of the buys and sells.
New Purchases: 2914, Added Positions: 6098, 8316, 7936, 4543, 6326, 7309, 6367, 8113, 9962, 4452,
For the details of Hennessy Japan Fund’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Hennessy+Japan+Fund
These are the top 5 holdings of Hennessy Japan FundASICS Corp (7936) – 551,100 shares, 5.67% of the total portfolio. Shares added by 45.95%SoftBank Group Corp (9984) – 126,200 shares, 5.56% of the total portfolio. Shares added by 2.10%MISUMI Group Inc (9962) – 490,600 shares, 5.41% of the total portfolio. Shares added by 9.29%Terumo Corp (4543) – 254,700 shares, 5.41% of the total portfolio. Shares added by 27.54%Kubota Corp (6326) – 590,900 shares, 5.41% of the total portfolio. Shares added by 27.38%New Purchase: Japan Tobacco Inc (2914)
Hennessy Japan Fund initiated holdings in Japan Tobacco Inc. The purchase prices were between $3615 and $3856, with an estimated average price of $3728.44. The stock is now traded at around $3860.00. The impact to the portfolio due to this purchase was 5.3%. The holdings were 273,700 shares as of 2017-04-30.
Top Value Stocks For 2018: Waste Management, Inc.(WM)
- [By Brian Feroldi]
Investors in their 60’s should start to favor low-risk stocks that offer up big dividend payouts. Below are three stocks — Waste Management (NYSE:WM), United Parcel Service (NYSE:UPS), and Welltower (NYSE:HCN) — that perfectly fit that description.
- [By ]
In the Lightning Round, Cramer was bullish on The Blackstone Group (BX) , Nvidia (NVDA) , Amgen (AMGN) , Regeneron Pharmaceuticals (REGN) , Hasbro (HAS) and Waste Management (WM) .
- [By Lisa Levin]
Some of the stocks that may grab investor focus today are:
Wall Street expects Avon Products, Inc. (NYSE: AVP) to report quarterly earnings at $0.10 per share on revenue of $1.62 billion before the opening bell. Avon Products shares rose 2.39 percent to $6.00 in after-hours trading.
Analysts expect MGM Resorts International (NYSE: MGM) to report quarterly earnings at $0.20 per share on revenue of $2.44 billion before the opening bell. MGM shares rose 1.01 percent to $29.90 in after-hours trading.
Cisco Systems, Inc. (NASDAQ: CSCO) reported better-than-expected results for its second quarter and raised its quarterly dividend to $0.29 per share. Cisco shares rose 2.13 percent to $33.52 in the after-hours trading session.
Before the markets open, Dean Foods Co (NYSE: DF) is projected to report its quarterly earnings at $0.41 per share on revenue of $2.01 billion. Dean Foods shares rose 0.49 percent to $20.55 in after-hours trading.
Tripadvisor Inc (NASDAQ: TRIP) posted weaker-than-expected results for its fourth quarter on Wednesday. Tripadvisor shares dropped 5.60 percent to $49.75 in the after-hours trading session.
Analysts are expecting Waste Management, Inc. (NYSE: WM) to have earned $0.77 per share on revenue of $3.42 billion in the latest quarter. Waste Management will release earnings before the markets open. Waste Management shares rose 2.27 percent to $72.97 in after-hours trading.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Waste Management (WM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By ]
Waste Management (WM) : “This is a high quality stock so I’m not going to bet against it.”
The Blackstone Group (BX) : “I think this is a terrific buy.”
Top Value Stocks For 2018: Colliers International Group Inc. (CIGI)
- [By Lee Jackson]
A10% owner of Colliers International Group Inc. (NASDAQ: CIGI) wasadding to holdings last week. Spruce House Partners bought a total of 133,800 shares of the company at $42.05 per share. The total for the buy was listed at $6 million.
- [By Joseph Griffin]
A number of hedge funds have recently made changes to their positions in the business. Beutel Goodman & Co Ltd. acquired a new position in Colliers International Gr during the fourth quarter valued at approximately $117,633,000. Renaissance Technologies LLC lifted its position in Colliers International Gr by 4.5% during the fourth quarter. Renaissance Technologies LLC now owns 859,200 shares of the financial services provider’s stock valued at $51,856,000 after buying an additional 36,800 shares in the last quarter. Mackenzie Financial Corp lifted its position in Colliers International Gr by 305.1% during the fourth quarter. Mackenzie Financial Corp now owns 305,329 shares of the financial services provider’s stock valued at $18,427,000 after buying an additional 229,960 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Colliers International Gr by 31.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 261,450 shares of the financial services provider’s stock valued at $15,779,000 after buying an additional 62,834 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Colliers International Gr by 25.2% during the fourth quarter. Deutsche Bank AG now owns 234,768 shares of the financial services provider’s stock valued at $14,168,000 after buying an additional 47,253 shares in the last quarter. 72.69% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Colliers International Gr (CIGI) Lifted to Hold at Zacks Investment Research” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at www.tickerreport.com/bankin
Top Value Stocks For 2018: TESARO, Inc.(TSRO)
- [By Ben Levisohn]
Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.
Agence France-Presse/Getty Images
The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:
AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.
The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).
Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.
In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?
Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.
UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:
This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth
- [By Chris Lange]
Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.
- [By Ben Levisohn]
Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:
Top Value Stocks For 2018: TNR Gold Corp. (TRRXF)
- [By SEEKINGALPHA.COM]
ILC is fully funded to at least the end of 2017. They have reasonable insider ownership (Chairman/CEO/President Kirill Klip owns 9.98%), partner ownership (Ganfeng 19%), plus TNR Gold (OTC:TRRXF) with 17.1% are the top 3 shareholders.